Clinical Trial Update: Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RDX-002's effect on postprandial triglycerides in patients discontinuing GLP-1 agonists; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hypertriglyceridemia
• Obesity

Drugs mentioned

• RDX-002

Snippet

Sponsor: Response Pharmaceuticals | Conditions: Triglycerides, Weight Gain Trajectory | Phase 2 | Status: COMPLETED